Preclinical Comparison of Two Hypomethylating Nucleosides in Tumor-Bearing Dogs

What qualifies my pet for enrollment in this in this trial?

• Body weight of ≥15kg
• Histologically confirmed lymphoma or solid tumor accessible for repeated biopsy
• Lymphoma may be confirmed by pre-treatment biopsy or cytology
• Favorable performance status (grade 0 or 1)
• No significant other health problems
• Dogs must be off all chemotherapy (except L-asparaginase) and radiation therapy for 2 weeks prior to study enrollment

• Both newly diagnosed dogs and those with recurrent/relapsed disease are eligible

   

What does enrolling my pet in this clinical trial involve?

A biopsy will be collected from your dog prior to the first dose of drug (pre-treatment), on Day 8, Day 12 and possibly on Day 22 depending on how your dog has responded to therapy. Each biopsy will occur under anesthesia, either local (sedation with anesthetic) or general. Your dog will return to the Veterinary Medical Center on Days 8, 12, 15 and 22. Serial blood collections (5 time points) will occur on Day 1 of the study. Subsequent, single time point collections will occur on Days 8, 12, 15 and 22. You will be required to administer doses of TdCyd or Aza-TdC at home on Days 2, 3, 4 and 5 and on Days 9, 10, 11. Your clinician will provide instructions on when and how to provide this medication to your dog.

Client Compensation

Most costs associated with this study will be covered as part of your participation. The management of any complications arising from study drug administration will be covered by study funds up to $1,250/per dog/event.